Aurobindo Pharma Limited
Aurobindo Pharma Limited (AUROPHARMA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
aurobindo.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,219 Cr | 7,352 Cr | 7,580 Cr | 7,567 Cr | 7,796 Cr | 7,979 Cr | 8,382 Cr | 7,868 Cr | 8,286 Cr | 8,646 Cr | 8,853 Cr | 9,150 Cr |
| Operating expenses (approx.) | 5,846 Cr | 5,750 Cr | 5,907 Cr | 5,947 Cr | 6,230 Cr | 6,401 Cr | 6,590 Cr | 6,265 Cr | 6,608 Cr | 6,873 Cr | 7,101 Cr | 7,269 Cr |
| EBITDA | 1,373 Cr | 1,601 Cr | 1,673 Cr | 1,620 Cr | 1,566 Cr | 1,578 Cr | 1,792 Cr | 1,603 Cr | 1,678 Cr | 1,773 Cr | 1,753 Cr | 1,881 Cr |
| OPM % | 19.0% | 21.8% | 22.1% | 21.4% | 20.1% | 19.8% | 21.4% | 20.4% | 20.3% | 20.5% | 19.8% | 20.6% |
| Other income | 187 Cr | 163 Cr | 136 Cr | 221 Cr | 136 Cr | 157 Cr | 135 Cr | 105 Cr | 121 Cr | 188 Cr | 117 Cr | 264 Cr |
| Interest | 68 Cr | 76 Cr | 89 Cr | 111 Cr | 113 Cr | 118 Cr | 115 Cr | 98 Cr | 95 Cr | 93 Cr | 98 Cr | 102 Cr |
| Depreciation | 418 Cr | 423 Cr | 354 Cr | 404 Cr | 382 Cr | 419 Cr | 444 Cr | 406 Cr | 429 Cr | 465 Cr | 479 Cr | 487 Cr |
| Profit before tax | 1,076 Cr | 1,262 Cr | 1,230 Cr | 1,324 Cr | 1,207 Cr | 1,200 Cr | 1,335 Cr | 1,207 Cr | 1,276 Cr | 1,339 Cr | 1,291 Cr | 1,515 Cr |
| Tax % | 30.1% | 25.5% | 26.2% | 30.6% | 32.3% | 29.5% | 32.4% | 31.7% | 33.5% | 32.0% | 28.7% | 31.9% |
| Net profit | 752 Cr | 940 Cr | 907 Cr | 918 Cr | 817 Cr | 846 Cr | 903 Cr | 824 Cr | 848 Cr | 910 Cr | 921 Cr | 1,032 Cr |
| EPS (₹) | ₹12.83 | ₹16.04 | ₹15.51 | ₹15.69 | ₹14.00 | ₹14.56 | ₹15.56 | ₹14.20 | ₹14.61 | ₹15.67 | ₹15.86 | ₹17.86 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 19,564 Cr | 23,099 Cr | 24,775 Cr | 23,455 Cr | 24,855 Cr | 29,002 Cr | 31,724 Cr | 33,653 Cr | Sign in for TTM |
| Operating expenses (approx.) | 15,672 Cr | 18,274 Cr | 19,441 Cr | 19,069 Cr | 21,137 Cr | 23,159 Cr | 25,141 Cr | 26,807 Cr | Sign in for TTM |
| EBITDA | 3,892 Cr | 4,825 Cr | 5,333 Cr | 4,387 Cr | 3,719 Cr | 5,843 Cr | 6,583 Cr | 6,846 Cr | Sign in for TTM |
| OPM % | 19.9% | 20.9% | 21.5% | 18.7% | 15.0% | 20.1% | 20.8% | 20.3% | Sign in for TTM |
| Other income | 116 Cr | 86 Cr | 381 Cr | 320 Cr | 291 Cr | 557 Cr | 622 Cr | 492 Cr | Sign in for TTM |
| Interest | 163 Cr | 160 Cr | 74 Cr | 49 Cr | 140 Cr | 290 Cr | 457 Cr | 384 Cr | Sign in for TTM |
| Depreciation | 668 Cr | 967 Cr | 1,055 Cr | 1,127 Cr | 1,245 Cr | 1,522 Cr | 1,649 Cr | 1,778 Cr | Sign in for TTM |
| Profit before tax | 3,091 Cr | 3,743 Cr | 7,344 Cr | 3,373 Cr | 2,613 Cr | 4,380 Cr | 5,066 Cr | 5,112 Cr | Sign in for TTM |
| Tax % | 23.5% | 24.4% | 27.4% | 21.5% | 26.2% | 27.6% | 31.2% | 31.5% | Sign in for TTM |
| Net profit | 2,365 Cr | 2,830 Cr | 5,334 Cr | 2,647 Cr | 1,928 Cr | 3,169 Cr | 3,484 Cr | 3,503 Cr | Sign in for TTM |
| EPS (₹) | ₹40.36 | ₹48.32 | ₹91.04 | ₹45.19 | ₹32.90 | ₹54.16 | ₹59.81 | ₹60.34 | Sign in for TTM |
| Dividend payout % | — | — | — | 10.0% | 22.8% | 8.3% | 0.0% | 6.6% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 59 Cr | 59 Cr | 59 Cr | 59 Cr | 59 Cr | 59 Cr | 58 Cr | 58 Cr |
| Reserves | 13,832 Cr | 16,752 Cr | 21,871 Cr | 24,517 Cr | 26,781 Cr | 29,784 Cr | 32,595 Cr | 37,833 Cr |
| Borrowings | 6,753 Cr | 5,422 Cr | 4,971 Cr | 2,373 Cr | 4,862 Cr | 6,315 Cr | 7,942 Cr | 7,676 Cr |
| Other liabilities | 5,809 Cr | 6,694 Cr | 6,954 Cr | 6,975 Cr | 8,177 Cr | 8,905 Cr | 9,196 Cr | 12,943 Cr |
| Total liabilities | 26,454 Cr | 28,926 Cr | 33,854 Cr | 33,922 Cr | 39,890 Cr | 45,072 Cr | 49,785 Cr | 58,502 Cr |
| Fixed assets (net) | 5,694 Cr | 6,495 Cr | 6,887 Cr | 7,728 Cr | 7,995 Cr | 11,546 Cr | 12,189 Cr | 14,330 Cr |
| CWIP | 1,342 Cr | 1,622 Cr | 2,429 Cr | 2,938 Cr | 4,496 Cr | 2,739 Cr | 3,266 Cr | 3,009 Cr |
| Investments | 360 Cr | 555 Cr | 591 Cr | 997 Cr | 543 Cr | 372 Cr | 252 Cr | 1,051 Cr |
| Loans & advances | 10 Cr | 14 Cr | 14 Cr | 13 Cr | 12 Cr | 13 Cr | 16 Cr | 18 Cr |
| Inventories | 7,246 Cr | 7,700 Cr | 9,027 Cr | 7,554 Cr | 8,511 Cr | 9,808 Cr | 10,544 Cr | 12,053 Cr |
| Trade receivables | 3,414 Cr | 4,315 Cr | 3,503 Cr | 4,012 Cr | 4,466 Cr | 4,817 Cr | 5,746 Cr | 7,094 Cr |
| Cash & bank | 1,886 Cr | 2,764 Cr | 5,373 Cr | 4,163 Cr | 4,396 Cr | 3,393 Cr | 5,569 Cr | 7,191 Cr |
| Other assets | 6,503 Cr | 5,463 Cr | 6,030 Cr | 6,517 Cr | 9,469 Cr | 12,383 Cr | 12,204 Cr | 13,756 Cr |
| Total assets | 26,454 Cr | 28,926 Cr | 33,854 Cr | 33,922 Cr | 39,890 Cr | 45,072 Cr | 49,785 Cr | 58,502 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 5,016 Cr | 2,387 Cr | 2,435 Cr | 3,925 Cr | 5,526 Cr |
| Cash from investing | — | — | — | -3,215 Cr | -3,978 Cr | -4,256 Cr | -1,875 Cr | -3,458 Cr |
| Cash from financing | — | — | — | -2,969 Cr | 1,814 Cr | 800 Cr | 120 Cr | -1,269 Cr |
| Net cash flow | — | — | — | -1,167 Cr | 223 Cr | -1,007 Cr | 2,178 Cr | 1,628 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 2,312 Cr | -334 Cr | -1,127 Cr | 1,405 Cr | 2,422 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 15.8% | 23.2% | 33.8% | 13.9% | 8.7% | 12.9% | 13.6% | 12.1% |
| ROE % | 17.0% | 16.8% | 24.3% | 10.8% | 7.2% | 10.6% | 10.7% | 9.3% |
| Debtor days | 64 | 68 | 51 | 62 | 65 | 61 | 66 | 77 |
| Inventory days | 354 | 364 | 395 | 373 | 321 | 332 | 357 | 426 |
| Days payable | 131 | 120 | 122 | 133 | 146 | 151 | 142 | 197 |
| Cash conversion cycle | 287 | 312 | 324 | 302 | 240 | 242 | 281 | 306 |
| Debt / equity | 0.49 | 0.32 | 0.23 | 0.10 | 0.18 | 0.21 | 0.24 | 0.20 |
| Current ratio | 1.28 | 1.44 | 1.85 | 2.21 | 1.87 | 1.95 | 1.85 | 1.81 |
| Net debt / EBITDA | 1.25 | 0.00 | 0.00 | 0.00 | 0.13 | 0.50 | 0.36 | 0.07 |
Compare with peers
Loading peers…